TX-MOUSER-ELECTRONICS
24.1.2022 20:12:08 CET | Business Wire | Press release
Mouser Electronics , Inc., the New Product Introduction (NPI) leader™ empowering innovation, is excited to partner with the DRAGON / PENSKE AUTOSPORT team for the ABB Formula E FIA World Championship series’ eighth season, which kicks off with double-header races at Diriyah E-Prix on January 28 and 29. The fourth consecutive season-opener at Diriyah gives fans two exciting night races just outside Saudi Arabia’s capital of Riyadh.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220124005567/en/
Mouser is partnering with the DRAGON / PENSKE AUTOSPORT team throughout the 2021–22 ABB FIA Formula E World Championship racing season, in collaboration with TTI, Inc . and valued manufacturers Molex and KYOCERA AVX . This is the eighth-straight year that Mouser and Molex have sponsored Formula E racing.
Driver Sérgio Sette Câmara returns to the team to helm the No. 7 Penske EV-5 car, while Formula 1 reserve driver Antonio Giovinazzi joins the team to take the wheel of the No. 6 car. The new season serves up 16 races, including stops in Jakarta, Vancouver, and Seoul, plus increased car power and new race qualifying formats.
“Mouser is thrilled to team up with Molex, TTI and KYOCERA AVX to partner with DRAGON / PENSKE AUTOSPORT for the eighth year in a row,” said Todd McAtee, Vice President, Americas Business Development for Mouser Electronics. “Formula E’s focus on developing and incorporating the latest in electric vehicle technology resonates with Mouser, our customers, and our fans and followers. We wish Sette Câmara, Giovinazzi, and the team the best this season!”
"TTI is pleased to team up with Mouser in supporting this exciting sport and its spotlight on sustainable automotive technologies of the future,” said Mike Morton, TTI Chief Executive Officer.
“This new chapter of Formula E promises to continue the evolution of this thrilling sport and serves as a powerful showcase for its electric future,” said Fred Bell, Vice President of Global Distribution for Molex. “Mouser and Molex have been proud supporters since the inception of Formula E, and we wish the DRAGON / PENSKE AUTOSPORT team a safe and successful season.”
“We’re delighted to collaborate with Mouser, Molex, and TTI in our partnership with the DRAGON / PENSKE AUTOSPORT Formula E racing team for another exciting season,” said Alex Schenkel, KYOCERA AVX’s Senior Vice President of Global Sales.
The Formula E series features cars that are powered solely by electricity and represent a vision for the future of the motor sports industry, serving as a framework for research and development around zero-emission motoring. The Gen2 cars offer a huge step forward in electric vehicle racing technology, with maximum power of 250 kW and speeds up to 280 km/h. Racing is all about speed and endurance, and racing partnerships are an innovative way for Mouser to communicate its performance-driven business model and promote the newest technologies from its manufacturer partners.
Fans can cast a vote for Sette Câmara and Giovinazzi in FANBOOST , which allows fans to play an active role in influencing the outcome of the race. FANBOOST gives fans the opportunity to vote for their favorite driver and award them an extra boost of power during the race. The five drivers with the most FANBOOST votes are awarded a significant burst of power, which they can deploy in a 5-second window during the second half of the race. FANBOOST voting for the Diriyah E-Prix opens January 25 and is available up to 15 minutes into the race.
To learn more, visit https://www.mouser.com/formula-e/ .
For more Mouser news, visit https://www.mouser.com/newsroom/ .
As a global authorized distributor, Mouser offers the world’s widest selection of the newest semiconductors and electronic components — in stock and ready to ship™. Mouser’s customers can expect 100% certified, genuine products that are fully traceable from each of its manufacturer partners. To help speed customers’ designs, Mouser’s website hosts an extensive library of technical resources, including a Technical Resource Center , along with product data sheets, supplier-specific reference designs, application notes, technical design information, engineering tools and other helpful information.
Engineers can stay abreast of today’s exciting product, technology and application news through Mouser’s complimentary e-newsletter. Mouser’s email news and reference subscriptions are customizable to the unique and changing project needs of customers and subscribers. No other distributor gives engineers this much customization and control over the information they receive. Learn about emerging technologies, product trends and more by signing up today at https://sub.info.mouser.com/subscriber .
About Mouser Electronics
Mouser Electronics, a Berkshire Hathaway company, is an authorized semiconductor and electronic component distributor focused on New Product Introductions from its leading manufacturer partners. Serving the global electronic design engineer and buyer community, the global distributor's website, mouser.com, is available in multiple languages and currencies and features more than 5 million products from over 1,200 manufacturer brands. Mouser offers 27 support locations worldwide to provide best-in-class customer service in local language, currency and time zone. The distributor ships to over 630,000 customers in 223 countries/territories from its 1 million-square-foot, state-of-the-art distribution facilities in the Dallas, Texas, metro area. For more information, visit https://www.mouser.com/ .
Trademarks
Mouser and Mouser Electronics are registered trademarks of Mouser Electronics, Inc. All other products, logos, and company names mentioned herein may be trademarks of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220124005567/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom